Insight on Pharmaceuticals and Healthcare

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

In-depth analysis of the osteoporosis drug pipeline, including a review of clinical unmet needs, assessment of the clinical and commercial prospects of 12 key late-stage agents, sales forecasts to 2019 and key opinion leader insight.

Published By Datamonitor
21 Jul 2010 $11400
Buy
Report
Report

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape

Overview of the Australian pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
29 Jul 2010 $7600
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy
Report
Report

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

This report covers 4 STDs: chlamydia, gonorrhea, human papillomavirus (HPV), and herpes simplex virus type 2 (HSV-2). It discusses disease background, epidemiology, unmet needs as well as marketed and pipeline therapeutic and preventative strategies.

Published By Datamonitor
05 Aug 2010 $3800
Buy
Report
Report

Japan Pharmaceutical Market Overview - Regulatory reforms will stimulate generics uptake

Overview of the Japanese pharmaceutical market including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
16 Aug 2010 $11400
Buy
Report
Report

Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions

An overview of merger and acquisition (M&A) trends in developed and emerging pharmaceutical markets in the Asia-Pacific region from Q1 2007 to Q1 2010, with discussion of the drivers of recent deals and analysis of key M&As in individual countries.

Published By Datamonitor
19 Aug 2010 $7600
Buy
Report
Report

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Analysis of the current and future moderate to severe chronic nociceptive pain market with sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key brands, generics, and pipeline products.

Published By Datamonitor
20 Aug 2010 $15200
Buy
Report
Report

Brazil Pharmaceutical Market Overview - Expanding healthcare access drives double-digit sales growth

Overview of the pharmaceutical market in Brazil including socioeconomic and demographic trends, regulatory issues, generics and biosimilars analysis and pharmaceutical company infrastructure analysis.

Published By Datamonitor
26 Aug 2010 $7600
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.